Thrombogenic mechanisms of antiphospholipid antibodies

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 79-82

  Esmon, Naomi L ^a   Smirnov, Mikhail D ^b   Esmon, Charles T ^b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN; LUPUS ANTICOAGULANT; MEMBRANE PROTEIN; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PROTHROMBIN;

ANTIBODY BLOOD LEVEL; BLOOD CLOTTING; CONFERENCE PAPER; CONTROLLED STUDY; GENETICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RISK FACTOR; THROMBOGENICITY; THROMBOSIS;

EID: 0030746610     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657505     Document Type: Conference Paper

References (26)

1. Triplett DA. Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause? Arch Pathol Lab Med 1993;117:78-88.
2. Esmon NL, Smirnov MD, Esmon CT. Lupus anticoagulants and thrombosis: The role of phospholipids. [In Press] Haematologia 1997.
3. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994;84:2854-67.
4. Sugi T, McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996;76:354-60.
5. Mohan Rao LV, Hoang AD, Rapaport SI. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996;88:4173-82.
6. Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density H-poprotein. J Clin Invest 1996;98:815-25.
7. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995;74:1120-5.
8. Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, Acland R, Harris EN. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemostas 1994;71:670-4.
9. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am J Obstet Gynecol 1993;168:206-10.
10. Stegnar M, Bozic B, Peternel P, Kveder T, Vene N, Rozman B. Prevalence of antiphospholipid antibodies in deep vein thrombosis and their relationship to blood coagulation and fibrinolysis. Thromb Res 1991;63:433-43.
11. Kimberly RP, Salmon JE, Edberg JC. Receptors for immunoglobulin G. Molecular diversity and implications for disease. Arthritis Rheum 1995;38:306-14.
12. Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fcgamma receptor IIA and Fcgamma receptor IIIB: Independent mechanisms for differences in human phagocyte function. J Clin Invest 1992;89:1274-81.
13. Gibson J, Nelson M, Brown R, Salem H, Kronenberg H. Autoantibodies to thrombomodulin: Development of an enzyme immunoassay and a survey of their frequency in patients with the lupus anticoagulant. Thromb Haemost 1992;67:507-9.
14. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-25.
15. Bokarewa, M. Phospholipid antibodies and APC resistance phenomenon in patients with thrombosis. Ph.D Thesis. Karolinska Institute, 1995.
16. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Sem Hematol 1992;29:213-26.
17. Berard M, Chantome R, Marcelli A, Boffa M-C. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996;23:1369-74.
18. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994;269:816-9.
19. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995;95:309-16.
20. Smeets EF, Comfurius P, Bevers EM, Zwaal RFA. Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles. Thromb Res 1996;81:419-26.
21. Neuenschwander PF, Bianco-Fisher E, Rezaie AR, Morrissey JH. Phosphatidylethanolamine augments factor Vila-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry 1995;34:13988-93.
22. Gilbert GE, Arena AA. Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-serine. J Biol Chem 1995;270:18500-5.
23. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988;53:505-18.
24. Smirnov M, Rezaie AR, Regan LM, Esmon CT, Esmon NL. The PE dependence of activated protein C function is mediated through the gla-domain. [Abstract] Circulation 1996;94:I-694
25. Furie B, Diuguid CF, Jacobs M, Diuguid DL, Furie BC. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood 1990;75:344-9.
26. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995;5:141-8.